Trypanosoma cruzi infection induces up-regulation of cardiac muscarinic acetylcholine receptors in vivo and in vitro

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 9, 2008, Pages 796-803

  Peraza Cruces, K ^a   Gutierrez Guedez L ^a   Castaneda Perozo D ^a   Lankford, C R ^a   Rodriguez Bonfante C ^a   Bonfante Cabarcas, R ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

Chagas disease; Immunogenic theory; Muscarinic acetylcholine receptor; Neurogenic theory; Super sensitivity; Trypanosoma cruzi

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUCINE; MUSCARINIC RECEPTOR; QUINUCLIDINYL BENZILATE; TRITIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CHAGAS DISEASE; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DENERVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; PARASYMPATHETIC INNERVATION; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR UPREGULATION; SPRAGUE DAWLEY RAT; TRYPANOSOMA CRUZI;

RATTUS; TRYPANOSOMA CRUZI;

EID: 54349127921     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008000900009     Document Type: Article

References (40)

1. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98: 577-591.
2. Añez N, Crisante G, Rojas A, Díaz N, Añez-Rojas N, Carrasco H, et al. La cara oculta de la enfermedad de Chagas en Venezuela. Bol Malariol Salud Ambient 2003; 63: 45-57.
3. Rassi A, Tranchesi J, Tranchesi B. Doen&a de Chagas. In: Veronesi A (Editor), Doenças infecciosas parasitarias. 8th edn. Rio de Janeiro: Guanabara Koogan; 1991. p 674-705.
4. Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev 1999; 12: 210-223.
5. Milei J, Stornino R, Jorg M, Chiale P, Schetjman D, Sterin Borda L, et al. Patogenia. In: Storino R, Milei J (Editors), Enfermedad de Chagas. Buenos Aires: Editorial Doyma Argentina SA; 1994. p 103-128.
6. Davila DF, Santiago JJ, Odreman WA. Vagal dysfunction and the pathogenesis of chronic Chagas disease. Int J Cardiol 2005; 100: 337-339.
7. Blum A, Miller H. Role of cytokines in heart failure. Am Heart J 1998; 135: 181-186.
8. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986; 74: 1290-1302.
9. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989; 86: 6753-6757.
10. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990; 67: 753-763.
11. Sterin-Borda L, Borda E. Role of neurotransmitter autoantibodies in the pathogenesis of chagasic peripheral dysautonomia. Ann N Y Acad Sci 2000; 917: 273-280.
12. Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 2000; 25: 261-266.
13. 2+ currents. Cardiovasc Res 2003; 58: 55-65.
14. Pacioretty LM, Barr SC, Han WP, Gilmour RF Jr. Reduction of the transient outward potassium current in a canine model of Chagas' disease. Am J Physiol 1995; 268: H1258-H1264.
15. Mukherjee S, Belbin TJ, Spray DC, Iacobas DA, Weiss LM, Kitsis RN, et al. Microarray analysis of changes in gene expression in a murine model of chronic chagasic cardiomyopathy. Parasitol Res 2003; 91: 187-196.
16. Goin JC, Perez LC, Borda E, Sterin-Borda L. Modification of cholinergic-mediated cellular transmembrane signals by the interaction of human chagasic IgG with cardiac muscarinic receptors. Neuroimmunomodulation 1994; 1: 284-291.
17. Goin JC, Borda ES, Auger S, Storino R, Sterin-Borda L. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia. Heart 1999; 82: 273-278.
18. de Oliveira SF, Pedrosa RC, Nascimento JH, Campos de Carvalho AC, Masuda MO. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. Circulation 1997; 96: 2031-2037.
19. Fujino H, Kitamura Y, Yada T, Uehara T, Nomura Y. Stimulatory roles of muscarinic acetylcholine receptors on T cell antigen receptor/CD3 complex-mediated interleukin-2 production in human peripheral blood lymphocytes. Mol Pharmacol 1997; 51: 1007-1014.
20. + current in heart. Am J Physiol Heart Circ Physiol 2007; 292: H1737-H1746.
21. Torres A, Davila DF, Gottberg CF, Donis JH, Arata de Bellabarba G, Ramoni-Perazzi P. Heart rate responses to a muscarinic agonist in rats with experimentally induced acute and subacute chagasic myocarditis. Rev Inst Med Trop São Paulo 2000; 42: 219-224.
22. Tanowitz HB, Davies P, Wittner M. Alterations in acetylcholine receptors in experimental Chagas' disease. J Infect Dis 1983; 147: 460-466.
23. Matousek de Abel de la Cruz AJ, Burguera JL, Burguera M, Anez N. Changes in the total content of iron, copper, and zinc in serum, heart, liver, spleen, and skeletal muscle tissues of rats infected with Trypanosoma cruzi. Biol Trace Elem Res 1993; 37: 51-70.
24. Labrador Hernández MJ, Suárez Graterol OJ, Rodríguez-Bonfante C, Bonfante-Cabarcas RA. Electrocardiographic study of the cholinergic system in cyclophosphamide induced-Chagas dilated myocardiopathy in Trypanosoma cruzi infected rats. Invest Clin 2008; 49: 207-224.
25. Institute for Laboratory Animal Research (ILAR). Guide for the care and use of laboratory animals. Washington: National Academy Press; 1996.
26. Waterborg JH, Matthews HR. The Lowry method for protein quantitation. Methods Mol Biol 1994; 32: 1-4.
27. Perez CC, Tobar ID, Jimenez E, Castaneda D, Rivero MB, Concepcion JL, et al. Kinetic and molecular evidences that human cardiac muscle express non-M2 muscarinic receptor subtypes that are able to interact themselves. Pharmacol Res 2006; 54: 345-355.
28. Rocha NN, Garcia S, Gimenez LE, Hernandez CC, Senra JF, Lima RS, et al. Characterization of cardiopulmonary function and cardiac muscarinic and adrenergic receptor density adaptation in C57BL/6 mice with chronic Trypanosoma cruzi infection. Parasitology 2006; 133: 729-737.
29. Barnes PJ, Haddad EB, Rousell J. Regulation of muscarinic M2 receptors. Life Sci 1997; 60: 1015-1021.
30. Haddad EB, Rousell J, Lindsay MA, Barnes PJ. Synergy between tumor necrosis factor alpha and interleukin 1beta in inducing transcriptional down-regulation of muscarinic M2 receptor gene expression. Involvement of protein kinase A and ceramide pathways. J Biol Chem 1996; 271: 32586-32592.
31. Jackson DA, Nathanson NM. Regulation of expression and function of m2 and m4 muscarinic receptors in cultured embryonic chick heart cells by transforming growth factor-beta 1. Biochem Pharmacol 1997; 54: 525-527.
32. Samuel I, Zaheer A, Zaheer S, Fisher RA. Bile-pancreatic juice exclusion increases cholinergic M3 and CCK-A receptor expression and interleukin-6 production in ligation-induced acute pancreatitis. Am J Surg 2004; 188: 511-515.
33. Ribeiro AL, Gimenez LE, Hernandez CC, de Carvalho AC, Teixeira MM, Guedes VC, et al. Early occurrence of anti-muscarinic autoantibodies and abnormal vagal modulation in Chagas disease. Int J Cardiol 2007; 117: 59-63.
34. Medei E, Pedrosa RC, Benchimol Barbosa PR, Costa PC, Hernandez CC, Chaves EA, et al. Human antibodies with muscarinic activity modulate ventricular repolarization: basis for electrical disturbance. Int J Cardiol 2007; 115: 373-380.
35. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, et al. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 2005; 49: 1521-1528.
36. Sterin-Borda L, Joensen L, Bayo-Hanza C, Esteva M, Borda E. Therapeutic use of muscarinic acetylcholine receptor peptide to prevent mice chagasic cardiac dysfunction. J Mol Cell Cardiol 2002; 34: 1645-1654.
37. Talvani A, Rocha MO, Ribeiro AL, Borda E, Sterin-Borda L, Teixeira MM. Levels of anti-M2 and anti-beta 1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas' heart disease. Microbes Infect 2006; 8: 2459-2464.
38. Dutra WO, Gollob KJ, Pinto-Dias JC, Gazzinelli G, Correa-Oliveira R, Coffman RL, et al. Cytokine mRNA profile of peripheral blood mononuclear cells isolated from individuals with Trypanosoma cruzi chronic infection. Scand J Immunol 1997; 45: 74-80.
39. D'Angelo-Mendoza E, Rodriguez-Bonfante C, Camacho I, Martinez J, Perdomo T, Cabrera A, et al. Patients suffering dilated chagasic cardiopathy or non chagasic cardiopathy show increased levels of tumor necrosis factor alpha. Invest Clin 2005; 46: 229-240.
40. López L, Arai K, Jiménez E, Jiménez M, Pascuzzo C, Rodríguez-Bonfante C, et al. Las concentraciones séricas de interleucina 6 y proteína C reactiva se incrementan en la medida en que la enfermedad de Chagas evoluciona hacia el deterioro de la función cardíaca. Rev Esp Cardiol 2006; 59: 50-56.